The Oncology Institute, Inc. (STLN) - Total Liabilities
Based on the latest financial reports, The Oncology Institute, Inc. (STLN) has total liabilities worth $203.15 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See The Oncology Institute, Inc. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
The Oncology Institute, Inc. - Total Liabilities Trend (2022–2025)
This chart illustrates how The Oncology Institute, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check The Oncology Institute, Inc. (STLN) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
The Oncology Institute, Inc. Competitors by Total Liabilities
The table below lists competitors of The Oncology Institute, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chongqing Wangbian Electric (Group) Corp. Ltd.
SHG:603191
|
China | CN¥4.28 Billion |
|
W olf Photoelectric Technology Ltd
SHE:002962
|
China | CN¥383.58 Million |
|
Flexium Interconnect Inc
TW:6269
|
Taiwan | NT$13.05 Billion |
|
Wanxiang Doneed Co Ltd
SHG:600371
|
China | CN¥126.60 Million |
|
ZheJiang ZhongKe Magnetic Co. Ltd. A
SHE:301141
|
China | CN¥647.16 Million |
|
GurSel Turizm Tasimacilik Ve Servis Ticaret AS
IS:GRSEL
|
Turkey | TL4.69 Billion |
|
Zheshang Development Group Co Ltd
SHE:000906
|
China | CN¥48.49 Billion |
|
Nanjing Railway New Technology Co.Ltd.
SHE:301016
|
China | CN¥163.95 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down The Oncology Institute, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see The Oncology Institute, Inc. assets under control.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -8.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how The Oncology Institute, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for The Oncology Institute, Inc. (2022–2025)
The table below shows the annual total liabilities of The Oncology Institute, Inc. from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $180.38 Million | +6.65% |
| 2024-12-31 | $169.13 Million | +11.11% |
| 2023-12-31 | $152.22 Million | +9.91% |
| 2022-12-31 | $138.49 Million | -- |
About The Oncology Institute, Inc.
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educatio… Read more